Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 03, 2022

Excess Long-Term Morbidity Limited but Not Eliminated by the Use of ABVD and Limited-Field Radiotherapy in Stage I–IIA Hodgkin Lymphoma

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy
J. Clin. Oncol 2022 Jan 25;[EPub Ahead of Print], I Lagerlöf, H Fohlin, G Enblad, B Glimelius, C Goldkuhl, M Palma, L Åkesson, I Glimelius, D Molin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading